BiomX Inc. Stock Price

NYSEAM:PHGE Community·US$10.2m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

PHGE Share Price Performance

US$0.38

-0.35 (-48.02%)

US$0.38

-0.35 (-48.02%)

US$0.38

Thu, 13 Nov 25

Share Pricen/a

PHGE Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

7 Risks

1 Reward

View Full Analysis

BiomX Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.70
: 0%
: 0%
: 0%

View Full Analysis

About PHGE

Founded: 2015
Employees: 55
CEO: Jonathan Solomon
WebsiteView website: www.biomx.com

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.